S1418/BR006 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy

IRB17-103
Cancer, Cancer-Gynecologic
Grace Makari-Judson, MD

D'Amour Center for Cancer Care

3350 Main Street
Springfield, MA 01199

 

 

Triple Negative Breast Cancer, post neoadjuvant chemo
Rae Lynn Defeo
413-794-0255